Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
20 Jan 2020 7:00 am
RNS
Imfinzi, tremelimumab granted ODD in liver cancer
  7:00 am
RNS
FDA grants Lynparza Priority Review for PROfound
13 Jan 2020 7:01 am
RNS
Lynparza granted FDA Priority Review for PAOLA-1
  7:00 am
RNS
Update on Epanova Phase III STRENGTH trial
06 Jan 2020 7:01 am
RNS
Farxiga granted FDA heart failure Priority Review
  7:00 am
RNS
Lokelma approved in China for hyperkalaemia
02 Jan 2020 3:00 pm
RNS
Total Voting Rights
30 Dec 2019 7:00 am
RNS
US FDA approved Lynparza for pancreatic cancer
23 Dec 2019 7:00 am
RNS
Triple-combination approved in China for COPD
  7:00 am
RNS
Enhertu (trastuzumab deruxtecan) approved in US
20 Dec 2019 7:00 am
RNS
AstraZeneca divests rights to Arimidex and Casodex
17 Dec 2019 6:06 pm
RNS
FDA panel backs Lynparza use for pancreatic cancer
16 Dec 2019 7:00 am
RNS
Seroquel rights agreement complete: Europe, Russia
12 Dec 2019 7:00 am
RNS
Imfinzi approved in China for Stage III NSCLC
11 Dec 2019 1:00 pm
RNS
Trastuzumab deruxtecan achieves ORR of 60.9%
05 Dec 2019 7:00 am
RNS
Lynparza approved in China for 1L BRCAm ovarian
03 Dec 2019 7:00 am
RNS
AstraZeneca divests Seroquel rights: US and Canada
02 Dec 2019 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
29 Nov 2019 7:00 am
RNS
Imfinzi granted FDA Priority Review for SCLC
21 Nov 2019 6:15 pm
RNS
Calquence approved in CLL in the US
15 Nov 2019 7:00 am
RNS
Qtrilmet approved in the EU for treatment of T2D
14 Nov 2019 7:00 am
RNS
FDA accepts regulatory submission for selumetinib
12 Nov 2019 7:00 am
RNS
Anifrolumab demonstrated superiority in TULIP 2
11 Nov 2019 7:00 am
RNS
Roxadustat pooled analyses: no increased CV risk
08 Nov 2019 7:00 am
RNS
Roxadustat significantly increased haemoglobin
06 Nov 2019 2:10 pm
RNS
Calquence data to show improved progression-free
01 Nov 2019 3:00 pm
RNS
Total Voting Rights
30 Oct 2019 7:00 am
RNS
AstraZeneca divests rights to Seroquel and
28 Oct 2019 3:31 pm
RNS
Imfinzi and Imfinzi plus tremelimumab delayed
24 Oct 2019 7:00 am
RNS
AstraZeneca year-to-date and Q3 2019 results
21 Oct 2019 7:00 am
RNS
Farxiga approved in the US to reduce the risk of
17 Oct 2019 7:00 am
RNS
Trastuzumab deruxtecan granted FDA Priority Review
04 Oct 2019 3:04 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Fasenra approved in the US for self-administration
03 Oct 2019 4:00 pm
RNS
Director Declaration
01 Oct 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
AstraZeneca divests rights for Losec to Cheplaphar
  7:00 am
RNS
Update on US regulatory review of PT010 in COPD
30 Sep 2019 3:30 pm
RNS
Lynparza more than doubled the time without
  7:00 am
RNS
Tagrisso is the only 1st-line treatment for EGFR-
  7:00 am
RNS
Lynparza improved the time women lived without
23 Sep 2019 7:00 am
RNS
Qtrilmet recommended for approval in EU by CHMP
18 Sep 2019 7:00 am
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 8:38 am
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 7:11 am
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
Brilinta reduced the risk of cardiovascular events
  7:00 am
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 7:00 am
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 7:05 am
RNS
Fasenra granted US Orphan Drug Designation for
  7:00 am
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 7:00 am
RNS
Roxadustat approved in China for the treatment of
  7:00 am
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 7:00 am
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 7:00 am
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 7:00 am
RNS
Directorate Change
14 Aug 2019 7:00 am
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
  7:00 am
RNS
Calquence granted US Breakthrough Therapy Designat
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t